0000000000239958

AUTHOR

Rolf A. Stahel

showing 5 related works from this author

Prevalence and Clinical Outcomes for Patients With ALK Gene Rearrangement in Europe: Preliminary Results from the European Thoracic Oncology Platform…

2012

ABSTRACT Background The prevalence of ALK gene rearrangement (ALK+) in European patients with non-small cell lung cancer (NSCLC) is unknown. The Lungscape project provides a platform to evaluate its expression and clinical significance in a large cohort of patients with resected NSCLC from 13 European sites in 11 countries. Methods Participating sites retrospectively identified cases of NSCLC with clinical demographic and outcome data, and available tissue for research according to predefined protocol criteria. Local ethical and regulatory approvals were adhered to. Clinical data were entered to a central, secure database. Accepted cases on the basis of completeness of clinical data were as…

medicine.medical_specialtyTissue microarrayClinical pathologyALK Gene Rearrangementbusiness.industryHematologymedicine.diseaseOncologyInternal medicineThoracic OncologyCohortmedicineAdenocarcinomaImmunohistochemistryClinical significancebusinessAnnals of Oncology
researchProduct

Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology P…

2014

Purpose The prevalence of anaplastic lymphoma kinase (ALK) gene fusion (ALK positivity) in early-stage non–small-cell lung cancer (NSCLC) varies by population examined and detection method used. The Lungscape ALK project was designed to address the prevalence and prognostic impact of ALK positivity in resected lung adenocarcinoma in a primarily European population. Methods Analysis of ALK status was performed by immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) in tissue sections of 1,281 patients with adenocarcinoma in the European Thoracic Oncology Platform Lungscape iBiobank. Positive patients were matched with negative patients in a 1:2 ratio, both for IHC and for …

AdultMaleCancer Researchmedicine.medical_specialtyPathologyLung NeoplasmsPopulation610 Medicine & healthAdenocarcinoma of LungAdenocarcinomaGastroenterologyCohort Studies10049 Institute of Pathology and Molecular Pathologyhemic and lymphatic diseasesThoracic OncologyInternal medicinePrevalencemedicineHumansAnaplastic lymphoma kinase1306 Cancer ResearchAnaplastic Lymphoma KinaseLung cancereducationIn Situ Hybridization FluorescenceAgedNeoplasm Stagingeducation.field_of_studyLungbusiness.industryALK-PositiveReceptor Protein-Tyrosine KinasesMiddle Agedmedicine.diseaseImmunohistochemistryEuropeTreatment Outcomemedicine.anatomical_structureOncology10032 Clinic for Oncology and HematologyImmunohistochemistryAdenocarcinoma2730 OncologyFemalebusiness
researchProduct

Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO)

2016

The European Society for Medical Oncology (ESMO) is one of the leading societies of oncology professionals in the world. Approximately 30% of the 13 000 ESMO members are below the age of 40 and thus meet the society's definition of young oncologists (YOs). ESMO has identified the training and development of YOs as a priority and has therefore established a comprehensive career development programme. This includes a leadership development programme to help identify and develop the future leaders in oncology. Well-trained and highly motivated future generations of multidisciplinary oncologists are essential to ensure the optimal evolution of the field of oncology with the ultimate goal of pro…

Oncologymedicine.medical_specialtyCancer ResearchReviewFellowshipExecutive boardMultidisciplinary approachInternal medicineJournal ArticleMedicine15061507Leadership developmentbusiness.industryLeadership ProgrammeGénéralitésESMOTraining and developmentYoung OncologistsOncologyESMO; Fellowship; Leadership Programme; Preceptorship; Young OncologistsPreceptorshipPortfoliobusinessCareer developmentESMO; Fellowship; Leadership Programme; Preceptorship; Young Oncologists; Cancer Research; Oncology
researchProduct

Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC

2017

[EN] Background Reported prevalence of driver gene mutations in non-small-cell lung cancer (NSCLC) is highly variable and clinical correlations are emerging. Using NSCLC biomaterial and clinical data from the European Thoracic Oncology Platform Lungscape iBiobank, we explore the epidemiology of mutations and association to clinicopathologic features and patient outcome (relapse-free survival, time-to-relapse, overall survival). Methods Clinically annotated, resected stage I¿III NSCLC FFPE tissue was assessed for gene mutation using a microfluidics-based multiplex PCR platform. Mutant-allele detection sensitivity is¿>1% for most of the ~150 (13 genes) mutations covered in the multiplex test.…

0301 basic medicineOncologyMaleLung NeoplasmsDNA Mutational AnalysisKRAS MUTATIONSGene mutationmedicine.disease_cause0302 clinical medicinemultiplex mutation analysisCarcinoma Non-Small-Cell LungMultiplex mutation analysisPrevalenceMultiplexAnaplastic Lymphoma KinaseHETEROGENEITYAged 80 and overMutationSmokingHematologyMiddle AgedProto-Oncogene Proteins c-metProgression-Free SurvivalOncology030220 oncology & carcinogenesisAdenocarcinomaFemaleKRASPREDICT SURVIVALAdultmedicine.medical_specialtyEGFRCELL LUNG-CANCERPrognosis molecular stagingprognosis molecular stagingEGFR KRAS PIK3CAVALIDATION03 medical and health sciencesYoung AdultInternal medicineMultiplex polymerase chain reactionmedicineKRASTYROSINE KINASE INHIBITORSHumansProgression-free survivalLung cancerAgedNeoplasm Stagingbusiness.industryMICROBIOLOGIAADENOCARCINOMAAMPLIFICATIONPIK3CAmedicine.disease030104 developmental biologynon-small-cell lung cancerMutationOVEREXPRESSIONbusinessMultiplex Polymerase Chain ReactionNon-small-cell lung cancerAnnals of Oncology
researchProduct

Changing the education paradigm in oncology: ESO masterclass, 17 years of continuous success

2020

In this review, we summarize the history of the 41 Masterclasses in Clinical Oncology (MCO) organized by ESO or ESO-ESMO during the last 17 years. MCOs have been held in five different geographical regions including: a) Central Europe, b) Eastern Europe and Balkans, c) Baltic and Euroasia, d) Arab World and Southern European Countries and e) Latin America. More than 2.000 young oncologists have attended and more than 250 distinguished faculty members have actively participated. The program exposes students to sessions covering all major tumors ("big killers") and to spotlights updating information on various important cancers and related topics. Participants are able to present their own cl…

0301 basic medicineLatin Americans2720 HematologyLearning assessment610 Medicine & healthMedical Oncology03 medical and health sciences0302 clinical medicineSurveys and QuestionnairesMedicineTumor boardHumansSocieties MedicalClinical OncologyOncologistsMedical educationbusiness.industryTeachingHematologyTest (assessment)Europe030104 developmental biologyOncologyEducation Medical Graduate030220 oncology & carcinogenesis10032 Clinic for Oncology and Hematology2730 OncologyClinical casebusiness
researchProduct